|
Showing 1 - 5 of
5 matches in All Departments
In recent years, high-density DNA microarrays have revolutionized
biomedical research and drug discovery efforts by the
pharmaceutical industry. Their efficacy in identifying and
prioritizing drug targets based on their ability to confirm a large
number of gene expression measurements in parallel has become a key
element in drug discovery. Microarray Innovations: Technology and
Experimentation examines the incredibly powerful nature of array
technology and the ways in which it can be applied to understanding
the genomic basis of disease. Explores a myriad of applications in
use today This volume explores recent innovations in the microarray
field and tracks the evolution of the major platforms currently
used. The international panel of contributors presents a survey of
the past five years' research and advancements in microarray
methods and applications and their usage in drug discovery and
biomedical research. The contributions discuss improvements in
automation (array fabrication and hybridization), new substrates
for printing arrays, platform comparisons and contrasts,
experimental design, and data normalization and mining schemes.
They also review epigenomic array studies, electronic microarrays,
comparative genomic hybridization, microRNA arrays, and mutational
analyzes. In addition, the book provides coverage of important
clinical diagnostic arrays, protein arrays, and neuroscience
applications. Examines improved methodologies As microarrays have
evolved steadily over time from archetypical in-house complementary
DNA (cDNA) arrays to robust commercial oligonucleotide platforms,
there has been a migration to higher density biochips with
increasing content and better analytical methodologies. This
compendium summarizes the vast advances that have been made in this
technology, highlighting the supreme advantages of microarray-based
approaches in the field of biomedical research.
Environmental Contaminants and Endocrine Health focuses
specifically on contaminants with hormonal disrupting activities.
The book provides insights into the multiple effects of
endocrine-disrupting chemicals (EDCs) and their mechanism of action
(MoA) on metabolism, reproduction and the multiple physiological
roles of the endocannabinoid system which has recently been
indicated as new target. The content systematically covers EDC
sources and effects, EDCs as sources of disease and health
impairment in laboratory models, EDCs as the cause of disease and
health impairment in humans and wild species, and the removal of
hazardous pollutants from wastewaters to highlight intervention,
mitigation and adaptation for reduced threat. This content will be
a foundational resource for academic and research staff in
endocrinology and hormone toxicology as well as for professors,
researchers and students in these areas.
In recent years, high-density DNA microarrays have revolutionized
biomedical research and drug discovery efforts by the
pharmaceutical industry. Their efficacy in identifying and
prioritizing drug targets based on their ability to confirm a large
number of gene expression measurements in parallel has become a key
element in drug discovery. Microarray Innovations: Technology and
Experimentation examines the incredibly powerful nature of array
technology and the ways in which it can be applied to understanding
the genomic basis of disease. Explores a myriad of applications in
use today This volume explores recent innovations in the microarray
field and tracks the evolution of the major platforms currently
used. The international panel of contributors presents a survey of
the past five years' research and advancements in microarray
methods and applications and their usage in drug discovery and
biomedical research. The contributions discuss improvements in
automation (array fabrication and hybridization), new substrates
for printing arrays, platform comparisons and contrasts,
experimental design, and data normalization and mining schemes.
They also review epigenomic array studies, electronic microarrays,
comparative genomic hybridization, microRNA arrays, and mutational
analyzes. In addition, the book provides coverage of important
clinical diagnostic arrays, protein arrays, and neuroscience
applications. Examines improved methodologies As microarrays have
evolved steadily over time from archetypical in-house complementary
DNA (cDNA) arrays to robust commercial oligonucleotide platforms,
there has been a migration to higher density biochips with
increasing content and better analytical methodologies. This
compendium summarizes the vast advances that have been made in this
technology, highlighting the supreme advantages of microarray-based
appro
In the fiercely competitive pharmaceutical marketplace, your
organization cannot afford to spend excess dollars developing drugs
that will fail to get FDA approval or have profoundly poor
characteristics. Biochips as Pathways to Drug Discovery takes a
comprehensive look at how the industry faces these challenges,
using new technologies such as biochips to reduce the cost of drug
discovery and improve drug safety. The book explores the tools and
skills required at each step of the discovery process when using
biochips to determine biological outcomes. The authors provide an
in-depth review of the clinical and pharmacogenomic relevance of
biochips, ChIP-chip assays, and high-throughput approaches. They
discuss how biochips are used to develop biomarkers in the drug
discovery process, primarily for gene expression profiling and
Single Nucleotide Polymorphism (SNP) analysis. The book includes
coverage of experimental theory, quality control, clinical
laboratory sampling considerations, database concepts, industrial
laboratory design, and the analysis of the resultant large data
sets. It discusses the application of biochips to the study of
malaria, toxicogenomics, and SNPs, as well as intellectual property
and market overviews. The book concludes with a comprehensive
overview of how these chips are employed from early target
discovery through preclinical toxicology and on through to
pharmacogenomic and proof of concept studies in humans. Written in
an easily accessible style, the breadth of coverage introduces the
subject to those new to the field, while the depth of coverage
forms a foundation for future work. The book gives you the
knowledge required to leverage the technology into bona fide
discoveries. Daniel E. Levy, editor of the Drug Discovery Series,
is the founder of DEL BioPharma, a consulting service for drug
discovery programs. He also maintains a blog that explores organic
chemistry.
|
|